Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 520

1.
2.

Number needed to treat with rosuvastatin to prevent first cardiovascular events and death among men and women with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER).

Ridker PM, MacFadyen JG, Fonseca FA, Genest J, Gotto AM, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ; JUPITER Study Group..

Circ Cardiovasc Qual Outcomes. 2009 Nov;2(6):616-23. doi: 10.1161/CIRCOUTCOMES.109.848473. Epub 2009 Sep 22.

3.
7.

Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial.

Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, Macfadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ; JUPITER Trial Study Group..

Lancet. 2009 Apr 4;373(9670):1175-82. doi: 10.1016/S0140-6736(09)60447-5. Epub 2009 Mar 28.

PMID:
19329177
8.

Baseline characteristics of participants in the JUPITER trial, a randomized placebo-controlled primary prevention trial of statin therapy among individuals with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein.

Ridker PM, Fonseca FA, Genest J, Gotto AM, Kastelein JJ, Khurmi NS, Koenig W, Libby P, Lorenzatti AJ, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ; JUPITER Trial Study Group..

Am J Cardiol. 2007 Dec 1;100(11):1659-64. Epub 2007 Oct 24.

9.

Cardiovascular risk reduction: what do recent trials with rosuvastatin tell us?

Fabbri G, Maggioni AP.

Adv Ther. 2009 May;26(5):469-87. doi: 10.1007/s12325-009-0025-6. Epub 2009 May 14. Review.

PMID:
19444394
10.

[The JUPITER study: critical review of final results].

Urbinati S, Romanazzi S, Gambetti S.

G Ital Cardiol (Rome). 2009 Dec;10(11-12 Suppl 3):28S-32S. Italian.

PMID:
21298859
11.

Rosuvastatin: a review of its use in the management of dyslipidemia.

Scott LJ, Curran MP, Figgitt DP.

Am J Cardiovasc Drugs. 2004;4(2):117-38. Review. Erratum in: Am J Cardiovasc Drugs. 2005;5(2):130.

PMID:
15049723
12.

Predicting benefit from statins by C-reactive protein, LDL-cholesterol or absolute cardiovascular risk.

Stewart RA.

Future Cardiol. 2009 May;5(3):231-6. doi: 10.2217/fca.09.8.

PMID:
19656039
13.

The JUPITER trial: How will it change clinical practice?

Watson KE.

Rev Cardiovasc Med. 2009 Spring;10(2):91-6. Review.

PMID:
19593321
14.
15.

Tracking of high-sensitivity C-reactive protein after an initially elevated concentration: the JUPITER Study.

Glynn RJ, MacFadyen JG, Ridker PM.

Clin Chem. 2009 Feb;55(2):305-12. doi: 10.1373/clinchem.2008.120642. Epub 2008 Dec 18.

16.

One-year efficacy and safety of rosuvastatin + fenofibric acid combination therapy in patients with mixed dyslipidemia: evaluation of dose response.

Ferdinand KC, Davidson MH, Kelly MT, Setze CM.

Am J Cardiovasc Drugs. 2012 Apr 1;12(2):117-25. doi: 10.2165/11597940-000000000-00000.

PMID:
22263674
17.

Primary prevention of vascular events in patients with high levels of C-reactive protein: the JUPITER study.

Fonseca FA, Izar MC.

Expert Rev Cardiovasc Ther. 2009 Sep;7(9):1041-56. doi: 10.1586/erc.09.93.

PMID:
19764857
18.

Lipid-altering efficacy of the ezetimibe/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients.

Catapano AL, Davidson MH, Ballantyne CM, Brady WE, Gazzara RA, Tomassini JE, Tershakovec AM.

Curr Med Res Opin. 2006 Oct;22(10):2041-53.

PMID:
17022864
19.

Rosuvastatin and cardiovascular events in patients undergoing hemodialysis.

Fellström BC, Jardine AG, Schmieder RE, Holdaas H, Bannister K, Beutler J, Chae DW, Chevaile A, Cobbe SM, Grönhagen-Riska C, De Lima JJ, Lins R, Mayer G, McMahon AW, Parving HH, Remuzzi G, Samuelsson O, Sonkodi S, Sci D, Süleymanlar G, Tsakiris D, Tesar V, Todorov V, Wiecek A, Wüthrich RP, Gottlow M, Johnsson E, Zannad F; AURORA Study Group..

N Engl J Med. 2009 Apr 2;360(14):1395-407. doi: 10.1056/NEJMoa0810177. Epub 2009 Mar 30. Erratum in: N Engl J Med. 2010 Apr 15;362(15):1450.

20.

The gravity of JUPITER (Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin).

O'Keefe JH, Carter MD, Lavie CJ, Bell DS.

Postgrad Med. 2009 May;121(3):113-8. doi: 10.3810/pgm.2009.05.2010. Review.

PMID:
19491548

Supplemental Content

Support Center